PMV Pharmaceuticals Toekomstige groei

Future criteriumcontroles 0/6

De winst van PMV Pharmaceuticals zal naar verwachting dalen met 0.7% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 70.6% per jaar. De winst per aandeel zal naar verwachting groeien met 2.3% per jaar.

Belangrijke informatie

-0.7%

Groei van de winst

2.3%

Groei van de winst per aandeel

Biotechs winstgroei	28.3%
Inkomstengroei	70.6%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	13 Nov 2024

Recente toekomstige groei-updates

Recent updates

Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Deliver On Growth Plans?

Aug 04

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Apr 20

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Dec 22

We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth

Sep 08

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

May 10

PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans

Jan 11

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Sep 22

PMV Pharmaceuticals GAAP EPS of -$0.38 beats by $0.04

Aug 09

PMV Pharma joins Merck to study lead candidate with Keytruda

Jul 18

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Jun 09

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

Feb 23

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Nov 05

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

Jul 23

Winst- en omzetgroeiprognoses

NasdaqGS:PMVP - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	N/A	-95	-84	N/A	4
12/31/2025	N/A	-84	-76	N/A	6
12/31/2024	N/A	-59	-76	N/A	6
9/30/2024	N/A	-51	-48	-47	N/A
6/30/2024	N/A	-49	-46	-46	N/A
3/31/2024	N/A	-65	-58	-57	N/A
12/31/2023	N/A	-69	-57	-56	N/A
9/30/2023	N/A	-73	-61	-59	N/A
6/30/2023	N/A	-74	-64	-60	N/A
3/31/2023	N/A	-74	-68	-61	N/A
12/31/2022	N/A	-73	-72	-64	N/A
9/30/2022	N/A	-72	-67	-60	N/A
6/30/2022	N/A	-69	-61	-56	N/A
3/31/2022	N/A	-65	-54	-52	N/A
12/31/2021	N/A	-58	-48	-47	N/A
9/30/2021	N/A	-50	-46	-45	N/A
6/30/2021	N/A	-44	-41	-40	N/A
3/31/2021	N/A	-39	-38	-38	N/A
12/31/2020	N/A	-34	-33	-33	N/A
9/30/2020	N/A	-31	-28	-28	N/A
6/30/2020	N/A	-28	-26	-26	N/A
3/31/2020	N/A	-27	-25	-25	N/A
12/31/2019	N/A	-25	-22	-22	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat PMVP de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat PMVP de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat PMVP de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er wordt verwacht dat PMVP volgend jaar geen omzet zal hebben.

Hoge groei-inkomsten: Er wordt verwacht dat PMVP volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van PMVP naar verwachting over 3 jaar hoog zal zijn

PMV Pharmaceuticals Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 54% to US$5.67

Price target decreased by 39% to US$13.20

Price target decreased to US$38.50

Price target decreased to US$43.33

Price target decreased to US$49.00

Price target decreased to US$53.17

Recent updates

New major risk - Revenue and earnings growth

PMV Pharmaceuticals, Inc. Provides A Progress Update on PYNNACLE Clinical Trial

Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Deliver On Growth Plans?

PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from Russell 3000 Index

Insufficient new directors

PMV Pharmaceuticals, Inc., Annual General Meeting, Jun 06, 2024

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Price target decreased by 54% to US$5.67

PMV Pharmaceuticals, Inc. Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220c-Positive Solid Tumors

PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer

PMV Pharmaceuticals, Inc. Announces Workforce Reduction of Approximately 30%

New minor risk - Market cap size

PMV Pharmaceuticals, Inc. Announces Chief Financial Officer Changes

PMV Pharmaceuticals, Inc. Announces Chief Financial Officer Changes

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Price target decreased by 39% to US$13.20

New minor risk - Market cap size

PMV Pharmaceuticals, Inc. Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types with TP53 Y220C Mutation

New major risk - Share price stability

PMV Pharmaceuticals, Inc. to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth

New minor risk - Share price stability

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$38.50

PMV Pharmaceuticals, Inc. Announces Board Changes

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

PMV Pharmaceuticals GAAP EPS of -$0.38 beats by $0.04

PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

PMV Pharma joins Merck to study lead candidate with Keytruda

PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from Russell 2000 Growth Index

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

PMV Pharmaceuticals, Inc. Announces Preliminary Results from the Ongoing Phase 1/2 PYNNACLE Study of PC14586 in Patients

Price target decreased to US$43.33

PMV Pharmaceuticals, Inc. to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Price target decreased to US$49.00

PMV Pharmaceuticals, Inc., Annual General Meeting, Jun 02, 2022

Price target decreased to US$53.17

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Chief Medical Officer exercised options and sold US$103k worth of stock

Co-Founder notifies of intention to sell stock

Insider exercised options and sold US$88k worth of stock

COO & CFO exercised options and sold US$138k worth of stock

Co-Founder notifies of intention to sell stock

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

COO & CFO exercised options and sold US$137k worth of stock

PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from Russell 2500 Value Index

Co-Founder notifies of intention to sell stock

Key Executive exercised options and sold US$832k worth of stock

Co-Founder notifies of intention to sell stock

COO & CFO exercised options and sold US$137k worth of stock

Chief Medical Officer exercised options and sold US$120k worth of stock

PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Strong Position To Grow Its Business

PMV Pharmaceuticals, Inc. Appoints Guillermina Lozano to Scientific Advisory Board

New 90-day high: US$61.51

Do Institutions Own PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares?

PMV Pharmaceuticals, Inc. Doses First Patient in Phase 1/2 Study of PC14586, a First-In-Class Precision Oncology Therapy That Targets Mutant P53

PMV Pharmaceuticals reports Q3 results

Pmv Pharmaceuticals, Inc. Grants Fda Fast Track Designation of Pc14586 for the Treatment of Advanced Cancer Patients That Have Tumors with A P53 Y220c Mutation

PMV Pharmaceuticals, Inc. has completed an IPO in the amount of $211.77 million.

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven